A novel LC-MS/MS assay for heparan sulfate screening in the cerebrospinal fluid of mucopolysaccharidosis IIIA patients

Bioanalysis

Volumn 8, Issue 4, 2016, Pages 285-295

  Naimy, Hicham ^a   Powell, Kendall D ^b   Moriarity, John R ^b   Wu, Jiang ^a   McCauley, Thomas G ^a   Haslett, Patrick A J ^a,c   Barbier, Ann J ^a,d   Qiu, Yongchang ^a  

^a SHIRE   (United States)

^b LABORATORY CORPORATION OF AMERICA   (United States)

^c AGIOS PHARMACEUTICALS   (United States)

^d ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

fit for purpose validation; reductive amination; reversed phase chromatography; stable isotope labeling; surrogate disaccharides

Indexed keywords

4 BUTYLANILINE; DISACCHARIDE; HEPARAN SULFATE; UNCLASSIFIED DRUG;

ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DERIVATIZATION; HUMAN; HYDROPHOBICITY; ISOTOPE LABELING; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PROCESS DEVELOPMENT; SANFILIPPO SYNDROME; VALIDATION STUDY; ADOLESCENT; CEREBROSPINAL FLUID; CHILD; INFANT; ISOLATION AND PURIFICATION; LIMIT OF DETECTION; PRESCHOOL CHILD; PROCEDURES; REFERENCE VALUE; STANDARDS; TANDEM MASS SPECTROMETRY;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, LIQUID; HEPARITIN SULFATE; HUMANS; INFANT; LIMIT OF DETECTION; MUCOPOLYSACCHARIDOSIS III; REFERENCE VALUES; TANDEM MASS SPECTROMETRY;

EID: 84959057237     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.15.243     Document Type: Article

References (33)

1. Kjellen L, Lindahl U. Proteoglycans: structures and interactions. Ann. Rev. Biochem. 60, 443-475 (1991).
2. Yang B, Yang BL, Savani RC, Turley EA. Identification of a common hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CD44 and link protein. EMBO J. 13(2), 286-296 (1994).
3. Bernfield M, Gotte M, Park PW et al. Functions of cell surface heparan sulfate proteoglycans. Ann. Rev. Biochem. 68, 729-777 (1999).
4. Muenzer J. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol. Genet. Metab. 111(2), 63-72 (2014).
5. Kowalewski B, Lamanna WC, Lawrence R et al. Arylsulfatase g inactivation causes loss of heparan sulfate 3-o-sulfatase activity and mucopolysaccharidosis in mice. Proc. Natl Acad. Sci. USA 109(26), 10310-10315 (2012).
6. Meyer A, Kossow K, Gal A et al. Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (sanfilippo syndrome type a). Pediatrics 120(5), e1255-e1261 (2007).
7. Vellodi A. Lysosomal storage disorders. Br. J. Haematol. 128(4), 413-431 (2005).
8. Hemsley KM, Beard H, King BM, Hopwood JJ. Effect of high dose, repeated intra-CSF injection of sulphamidase on neuropathology in MPS IIIA mice. Genes Brain Behav, 7(7), 740-753 (2008).
9. Urayama A, Grubb JH, Sly WS, Banks WA. Mannose 6-phosphate receptor-mediated transport of sulfamidase across the blood-brain barrier in the newborn mouse. Mol. Ther. 16(7), 1261-1266 (2008).
10. Karousou EG, Viola M, Genasetti A et al. Application of polyacrylamide gel electrophoresis of fluorophore-labeled saccharides for analysis of hyaluronan and chondroitin sulfate in human and animal tissues and cell cultures. BMC 19(10), 761-765 (2005).
11. Shaklee PN, Conrad HE. Hydrazinolysis of heparin and other glycosaminoglycans. Biochem. J. 217(1), 187-197 (1984).
12. Calabro A, Midura R, Wang A, West L, Plaas A, Hascall VC. Fluorophore-assisted carbohydrate electrophoresis (face) of glycosaminoglycans. Osteoarthritis Cartilage 9(Suppl. A), S16-S22 (2001).
13. Shi X, Zaia J. Organ-specific heparan sulfate structural phenotypes. J. Biol. Chem. 284(18), 11806-11814 (2009).
14. Oguma T, Tomatsu S, Montano AM, Okazaki O. Analytical method for the determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography/turbo ionspray ionization tandem mass spectrometry. Anal. Biochem. 368(1), 79-86 (2007).
15. Gill VL, Wang Q, Shi X, Zaia J. Mass spectrometric method for determining the uronic acid epimerization in heparan sulfate disaccharides generated using nitrous acid. Anal. Chem. 84(17), 7539-7546 (2012).
16. Takegawa Y, Araki K, Fujitani N et al. Simultaneous analysis of heparan sulfate, chondroitin/dermatan sulfates, and hyaluronan disaccharides by glycoblotting-assisted sample preparation followed by single-step zwitter-ionichydrophilic interaction chromatography. Anal. Chem. 83(24), 9443-9449 (2011).
17. Gill VL, Aich U, Rao S, Pohl C, Zaia J. Disaccharide analysis of glycosaminoglycans using hydrophilic interaction chromatography and mass spectrometry. Anal. Chem. 85(2), 1138-1145 (2013).
18. Volpi N. High-performance liquid chromatography and on-line mass spectrometry detection for the analysis of chondroitin sulfates/hyaluronan disaccharides derivatized with 2-aminoacridone. Anal. Biochem. 397(1), 12-23 (2010).
19. Lawrence R, Olson SK, Steele RE et al. Evolutionary differences in glycosaminoglycan fine structure detected by quantitative glycan reductive isotope labeling. J. Biol. Chem. 283(48), 33674-33684 (2008).
20. Yang B, Chang Y, Weyers AM, Sterner E, Linhardt RJ. Disaccharide analysis of glycosaminoglycan mixtures by ultra-high-performance liquid chromatography-mass spectrometry. J. Chromatogr. A 1225, 91-98 (2012).
21. Bame KJ, Esko JD. Undersulfated heparan sulfate in a chinese hamster ovary cell mutant defective in heparan sulfate n-sulfotransferase. J. Biol. Chem. 264(14), 8059-8065 (1989).
22. Shapiro EG, Nestrasil I, Delaney KA et al. A prospective natural history study of mucopolysaccharidosis type IIIa. N. Engl. J. Med. (submitted).
23. Guidance for industry. Bioanalytical method validation (2001). www.fda.gov/downloads/drugs/guidance
24. Zhang H, Young SP, Auray-Blais C, Orchard PJ, Tolar J, Millington DS. Analysis of glycosaminoglycans in cerebrospinal fluid from patients with mucopolysaccharidoses by isotope-dilution ultra-performance liquid chromatography-tandem mass spectrometry. Clin. Chem. 57(7), 1005-1012 (2011).
25. Yoshida K, Miyauchi S, Kikuchi H, Tawada A, Tokuyasu K. Analysis of unsaturated disaccharides from glycosaminoglycuronan by high-performance liquid chromatography. Anal. Biochem. 177(2), 327-332 (1989).
26. Conboy JJ, Henion J. High-performance anion-exchange chromatography coupled with mass spectrometry for the determination of carbohydrates. Biol. Mass Spectrom. 21(8), 397-407 (1992).
27. Zaia J. On-line separations combined with MS for analysis of glycosaminoglycans. Mass Spectrom. Rev. 28(2), 254-272 (2009).
28. Osago H, Shibata T, Hara N et al. Quantitative analysis of glycosaminoglycans, chondroitin/dermatan sulfate, hyaluronic acid, heparan sulfate, and keratan sulfate by liquid chromatography-electrospray ionization-tandem mass spectrometry. Anal. Biochem. 467, 62-74 (2014).
29. Lawrence R, Brown JR, Al-Mafraji K et al. Diseasespecific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses. Nat. Chem. Biol. 8(2), 197-204 (2012).
30. Wei W, Miller RL, Leary JA. Method development and analysis of free hs and hs in proteoglycans from pre-and postmenopausal women: evidence for biosynthetic pathway changes in sulfotransferase and sulfatase enzymes. Anal. Chem. 85(12), 5917-5923 (2013).
31. Auray-Blais C, Bherer P, Gagnon R et al. Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI. Mol. Genet. Metab. 102(1), 49-56 (2011).
32. Zhang H, Young SP, Auray-Blais C, Orchard PJ, Tolar J, Millington DS. Analysis of glycosaminoglycans in cerebrospinal fluid from patients with mucopolysaccharidoses by isotope-dilution ultra-performance liquid chromatography-tandem mass spectrometry. Clin. Chem. 57(7), 1005-1012 (2011).
33. Volpi N, Maccari F, Galeotti F et al. Plasmatic dermatan sulfate and chondroitin sulfate determination in mucopolysaccharidoses. J. Pharm. Biomed. Anal. 85, 40-45 (2013).